ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 14 January 2026. At the meeting 10 977 485 shares were represented, which corresponds to approx. 36 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.
Allocation of the company’s result
The AGM resolved to adopt the income statement and balance sheet for the company as well as the consolidated income statement and consolidated balance sheet for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.
The AGM approved the board’s proposal that the result should be carried forward.
Fees to the board members and the auditors
The AGM agreed on the following fees to the board and the auditors.
Remuneration to non-employed board members elected by a general meeting shall be paid in the amount of SEK 150,000 to the chairman of the board and SEK 75,000 to each of the other board members.
Fees to the auditors shall be paid in accordance with approved invoices.
Board members, chairman of the board and auditors
The AGM agreed that the Board of Directors shall consist of five members without deputies. The AGM re-elected Karl Karlsson, Johan Strömqvist, Ramon Vila and Ivailo S. Georgiev as Board members. Johan Orvelin was elected as new Board member. Andreas Hedskog and Anil Okay were not re-elected. Ivailo S. Georgiev was re-elected as Chairman of the Board.
Ernst & Young AB was elected as the company’s auditor, with Martin Henriksson as auditor in charge.
Authorization for the board to decide on issue of new shares
The AGM resolved to authorize the board of Newbury Pharmaceuticals AB to decide to issue new shares in the company, in accordance with the board’s proposal.